{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,26]],"date-time":"2026-04-26T23:37:20Z","timestamp":1777246640028,"version":"3.51.4"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:00:00Z","timestamp":1776124800000},"content-version":"vor","delay-in-days":4,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Metronomic cyclophosphamide is sometimes considered in older or frail patients with advanced cancer when disease-related symptoms affect quality of life and standard treatments are no longer suitable. While clinical feedback on its tolerance and efficacy is often positive, the evidence remains limited in geriatric, comorbid populations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and methods<\/jats:title>\n                    <jats:p>This retrospective, monocentric study evaluated the impact of patient-, tumour-, and treatment-related characteristics on the efficacy and safety of metronomic cyclophosphamide in patients aged \u226570\u2009years with metastatic solid tumors. Baseline geriatric assessments were collected, and treatment exposure, tolerance, and outcomes were analyzed. An exploratory subgroup analysis focused on patients treated for \u22659\u2009months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Thirty-seven patients (median age 84\u2009years, range 70-96) were included: 15 had prostate cancer (40.5%), 8 breast cancer (21.6%), and 14 other primary tumors (37.8%). The median treatment duration was 4\u2009months; the median progression-free survival was 4\u2009months and 6\u2009months in breast and prostate cancer subgroups. Overall dose intensity was 87%, with 62.2% of patients maintaining \u226590%. Treatment was generally well tolerated; only 5 grade \u22653 toxicities were reported, and 83.7% of patients remained at home during therapy. Notably, patients treated for \u22659\u2009months had a poorer performance status and lower functional scores at baseline. No specific molecular alterations were associated with prolonged treatment benefit.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Metronomic cyclophosphamide appears to be a safe and potentially effective option in older and frail patients with metastatic cancer, including those with limited functional reserve. These findings support its use as a pragmatic alternative to supportive care, even in late disease stages.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyag130","type":"journal-article","created":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T11:38:22Z","timestamp":1775907502000},"source":"Crossref","is-referenced-by-count":0,"title":["Impact of geriatric covariates on metronomic cyclophosphamide efficacy and tolerance\u2014the CHEMETROLD study"],"prefix":"10.1093","volume":"31","author":[{"given":"Clara","family":"Griffe","sequence":"first","affiliation":[{"name":"Institut du Vieillissement, Hospices Civils de Lyon , Lyon 69002,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Ravot","sequence":"additional","affiliation":[{"name":"Service de G\u00e9riatrie, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon , Pierre-B\u00e9nite 69495,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3543-1674","authenticated-orcid":false,"given":"David","family":"Dayde","sequence":"additional","affiliation":[{"name":"Plateforme de recherche clinique de l\u2018Institut de Canc\u00e9rologie des Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon , Pierre-B\u00e9nite 69495,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7267-4723","authenticated-orcid":false,"given":"Claire","family":"Falandry","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Lyon1, INSERM, INRAE, CarMeN , Pierre-B\u00e9nite 69495,","place":["France"]},{"name":"Service de G\u00e9riatrie, Centre Hospitalier Croix-Rousse, Hospices Civils de Lyon , Lyon 69004,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2026,4,13]]},"reference":[{"key":"2026042618470809100_oyag130-B1","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1177\/107327480701400103","article-title":"Interaction between comorbidity and cancer","volume":"14","author":"Extermann","year":"2007","journal-title":"Cancer Control."},{"key":"2026042618470809100_oyag130-B2","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.1749-6632.2000.tb06651.x","article-title":"Inflamm-aging. An evolutionary perspective on immunosenescence","volume":"908","author":"Franceschi","year":"2000","journal-title":"Ann N Y Acad Sci"},{"key":"2026042618470809100_oyag130-B3","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S0047-6374(97)00153-X","article-title":"Altered cytokine production in the elderly","volume":"102","author":"Rink","year":"1998","journal-title":"Mech Ageing Dev"},{"key":"2026042618470809100_oyag130-B4","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1002\/(SICI)1097-0142(20000201)88:3<653::AID-CNCR24>3.0.CO;2-1","article-title":"Cancer and comorbidity: redefining chronic diseases","volume":"88","author":"Ogle","year":"2000","journal-title":"Cancer."},{"key":"2026042618470809100_oyag130-B5","doi-asserted-by":"crossref","first-page":"e5483791","DOI":"10.1155\/2019\/5483791","article-title":"Metronomic chemotherapy: a systematic review of the literature and clinical experience","volume":"2019","author":"Simsek","year":"2019","journal-title":"J Oncol"},{"key":"2026042618470809100_oyag130-B6","first-page":"4342","article-title":"Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells","volume":"63","author":"Bertolini","year":"2003","journal-title":"Cancer Res"},{"key":"2026042618470809100_oyag130-B7","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.ctrv.2014.06.002","article-title":"Metronomic therapy and breast cancer: a systematic review","volume":"40","author":"Montagna","year":"2014","journal-title":"Cancer Treat Rev"},{"key":"2026042618470809100_oyag130-B8","doi-asserted-by":"crossref","first-page":"30","DOI":"10.5301\/tj.5000207","article-title":"On and off metronomic oral vinorelbine in elderly women with advanced breast cancer","volume":"101","author":"De Iuliis","year":"2015","journal-title":"Tumori J"},{"key":"2026042618470809100_oyag130-B9","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/0277-9536(85)90335-1","article-title":"The quality of life of cancer patients: a review of the literature","volume":"20","author":"de Haes","year":"1985","journal-title":"Soc Sci Med"},{"key":"2026042618470809100_oyag130-B10","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/nrclinonc.2009.146","article-title":"Cyclophosphamide and cancer: golden anniversary","volume":"6","author":"Emadi","year":"2009","journal-title":"Nat Rev Clin Oncol"},{"key":"2026042618470809100_oyag130-B11","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.critrevonc.2011.04.009","article-title":"Cyclophosphamide-based metronomic chemotherapy: after 10 years of experience, where do we stand and where are we going?","volume":"82","author":"Penel","year":"2012","journal-title":"Crit Rev Oncol Hematol"},{"key":"2026042618470809100_oyag130-B12","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/0165-1781(92)90005-N","article-title":"Rating chronic medical illness burden in geropsychiatric practice and research: application of the cumulative illness rating scale","volume":"41","author":"Miller","year":"1992","journal-title":"Psychiatry Res"},{"key":"2026042618470809100_oyag130-B13","doi-asserted-by":"crossref","first-page":"S59","DOI":"10.1111\/j.1753-4887.1996.tb03793.x","article-title":"Assessing the nutritional status of the elderly: the mini nutritional assessment as part of the geriatric evaluation","volume":"54","author":"Guigoz","year":"1996","journal-title":"Nutr Rev"},{"key":"2026042618470809100_oyag130-B14","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1111\/j.1532-5415.1983.tb03391.x","article-title":"Assessing self-maintenance: activities of daily living, mobility, and instrumental activities of daily living","volume":"31","author":"Katz","year":"1983","journal-title":"J Am Geriatr Soc"},{"key":"2026042618470809100_oyag130-B15","first-page":"1141","article-title":"[Mini-Mental State Examination: a useful method for the evaluation of the cognitive status of patients by the clinician. Consensual French version]","volume":"28","author":"Derouesne","year":"1999","journal-title":"Presse Med"},{"key":"2026042618470809100_oyag130-B16","doi-asserted-by":"crossref","first-page":"e197","DOI":"10.1016\/j.clgc.2014.02.007","article-title":"Metronomic oral cyclophosphamide chemotherapy possibly contributes to stabilization of disease in patients with metastatic Castration-Resistant prostate cancer: a prospective analysis of consecutive cases","volume":"12","author":"Yashi","year":"2014","journal-title":"Clin Genitourin Cancer."},{"key":"2026042618470809100_oyag130-B17","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1093\/annonc\/mdj066","article-title":"Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects","volume":"17","author":"Colleoni","year":"2006","journal-title":"Ann Oncol"},{"key":"2026042618470809100_oyag130-B18","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1002\/cncr.26376","article-title":"Peak and decline in cancer incidence, mortality, and prevalence at old ages","volume":"118","author":"Harding","year":"2012","journal-title":"Cancer."},{"key":"2026042618470809100_oyag130-B19","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S1040-8428(01)00168-8","article-title":"The unexpected contribution of immunosenescence to the leveling off of cancer incidence and mortality in the oldest old","volume":"39","author":"Bonaf\u00e8","year":"2001","journal-title":"Crit Rev Oncol Hematol"},{"key":"2026042618470809100_oyag130-B20","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1093\/jnci\/86.17.1303","article-title":"Altered angiogenesis underlying age-dependent changes in tumor growth","volume":"86","author":"Pili","year":"1994","journal-title":"J Natl Cancer Inst"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyag130\/68077626\/oyag130.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/5\/oyag130\/68077626\/oyag130.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/5\/oyag130\/68077626\/oyag130.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,26]],"date-time":"2026-04-26T22:47:16Z","timestamp":1777243636000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyag130\/8653740"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,10]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,4,10]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyag130","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5]]},"published":{"date-parts":[[2026,4,10]]},"article-number":"oyag130"}}